US FDA lifts partial clinical hold on Kura Oncology's KOMET─001 phase 1b study of KO─539 to treat AML

Kura Oncology, Inc., a clinical─stage biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has lifted the partial clinical hold on the KOMET─001 phase 1b study of KO─539 in